Teresa Donnell
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 523 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 28.8% of the total. Reporting peaked in 2023 at $4,064 and has fallen 98.4% since, to $66 in 2024. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 523 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$1K
- Johnson & Johnson$737
- AstraZeneca$689
- UCB, Inc.$530
- GSK$480
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,04799%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 188 | $2,623 |
| Amgen(2 entities) | 65 | $1,235 |
| Johnson & Johnson | 33 | $737 |
| AstraZeneca(2 entities) | 36 | $689 |
| UCB, Inc. | 30 | $530 |
| GSK | 27 | $480 |
| Lilly USA, LLC | 15 | $399 |
| Novartis | 19 | $318 |
| Mallinckrodt Hospital Products Inc. | 16 | $304 |
| Boehringer Ingelheim | 13 | $272 |
| Aurinia Pharma U.S., Inc. | 16 | $262 |
| Actelion Pharmaceuticals US, Inc. | 8 | $222 |
| Pfizer | 13 | $216 |
| ANI Pharmaceuticals, Inc. | 8 | $204 |
| Genentech USA, Inc. | 7 | $130 |
| E.r. Squibb & Sons, L.L.C. | 8 | $114 |
| Sobi, Inc | 4 | $98 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Organon | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Tersera Therapeutics LLC | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Sandoz | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $11 |
How this compares
$9,114 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $147,969 |
| Hydroxychloroquine Sulfate | 61 | $4,974 |
| Duloxetine Hcl | 21 | $1,078 |
| MethotrexateMethotrexate Sodium | 22 | $555 |
| Sulfasalazine | 14 | $371 |
| Prednisone | 21 | $104 |
Paid to pharmacies, not to this prescriber.
Other family in Tulsa
- Candy WilliamsTulsa$22K
- Jillian OakleafTulsa$15K
- Lee MatlockTulsa$15K
- Vanessa ZickefooseTulsa$13K
- Erin RowanTulsa$13K
- Lora HortonTulsa$12K
- Darla NorrisTulsa$11K
- Cristina BarnesTulsa$11K
- Ashley RiouseTulsa$10K
- Jaclyn DrassTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.